Ferring has spared little expense in its efforts to get Adstiladrin to patients, including nearly $500 million in manufacturing investments.
Wednesday, August 13, 2025
After decades of research that hadn’t translated into efficacy in patients and a proliferation of unsubstantiated stem cell science, MSCs seemed stuck in therapeutic purgatory, unable to rise from the pyre and prove their validity.
Wednesday, August 06, 2025
With MSCs back in the spotlight and a pipeline of mid- and late-stage candidates pushing toward regulatory submission, what looms now is not a question of whether MSCs can deliver, but the challenge of turning decades of insights and technology advancements into the next generation of commercialized...
In 2025, a new challenge has taken center stage: A tightening macroeconomic environment that threatens to slow the pace of innovation.
Emerging cell types are broadening the treatment scope of cell therapy, while automation, PAT and strategic partnerships are addressing manufacturing challenges. Emphasizing the safety of these therapies will improve accessibility and build patient trust, ultimately enhancing the impact of CAR-T ...
The cutting edge of cancer research is now expanding beyond conventional T cells to a less-explored, unconventional, unique subset of T cell: mucosal-associated invariant T (MAIT) cells. Engineered MAIT cells may stand to change future allogeneic treatments for solid tumors.
Against a backdrop of historic charm, bold visions for the future of medicine were exchanged as attendees from all over the globe showed up in force to learn, present, collaborate and reconnect on all aspects of cell and gene therapies.
ISCT is an important event for meeting leaders in the field of cell therapy, exploring the biggest challenges and bottlenecks, and mapping out potential solutions.
ASGCT is an important meeting to get a lay-of-the-land for the research and early-stage progress for the field of gene therapy, and to help identify the key trends going into the next decade of development for advanced therapies.
Advances in interactive response technology platforms for drug supply can be highly beneficial when thoughtfully designed to address the unique challenges of CGT trials. This is especially true when these platforms are integrated into a comprehensive consultative approach led by specialized ...